CClinicalTrials.gg
Sign In
Active, not recruitingNCT05124405Updated May 20, 2026

Monitoring Your Exercise-related Metrics Over Time Via Wearable Electronic Devices

An interventional study of Fitbit and Continuous Glucose Monitor in Cancer and Diabetes, sponsored by M.D. Anderson Cancer Center. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-20.

Sponsored by M.D. Anderson Cancer Center · Not applicable, Interventional, and Prevention

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled May 2018, registered May 2019).
Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

To test the use of a continuous activity and heart rate tracker (Fitbit) and continuous glucose monitor (CGM) in monitoring daily exercise-related activities.

Read the detailed description

Primary objective:

To evaluate the feasibility of a CGM-based physical activity intervention that includes the use of CGM and Fitbit®.

Secondary objectives:

To examine changes in physical activity motivation and other related psychosocial variables (e.g., intention, perceived benefits, outcome expectancy) before and after the intervention.

Exploratory objective:

Examine cancer-related biomarkers and their associations with daily glucose pattern.

02

Conditions studied

  • Cancer
  • Diabetes
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 35 is below the median of 50 across 7,253 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

M.D. Anderson Cancer Center is the lead sponsor of 2,999 studies on the registry; 581 are open to participants now.

Of its 599 completed or terminated interventional studies of FDA-regulated products, 402 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Men and women at least 18 years old
  • Body mass index (BMI) 25 kg/m2
  • Engage in less than 150 minutes of moderate-intensity PA per week in the past month
  • Capable of participating in moderate-vigorous unsupervised exercise (as determined by the Physical Activity Readiness Questionnaire (PARQ) or a medical release from their physician)
  • Self-reported ability to walk one block without pain or discomfort
  • Have a smart phone with daily internet access that is compatible with the LibreLink app
  • Ability to speak, read, and write in English
  • For the cancer survivor cohort (participant accession number #21 and beyond), individuals must have been diagnosed with stage I-III breast or colorectal cancer and completed adjuvant therapy (i.e., chemo and/or radiation therapy).

Exclusion criteria

Exclusion Criteria:

  • Self-reported current diagnosis or history of type 1 diabetes or type 2 diabetes
  • Self-reported use of oral antidiabetic agents (OADs)
  • Previous or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness including gestational is allowed at the discretion for the investigator)
  • Current use of a continuous glucose monitor
  • Fasting glucose > 125 mg/dL
  • Pregnancy
  • Self-reported health issues that limit physical activity
  • On dialysis
  • Work overnight shifts
  • Unwilling to use CGM
  • Current participation in other wellness or weight loss-related program or intervention
  • Currently on a low-carb diet
  • Unable to receive REDCap survey through their mobile phones
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Heart Rate Tracker (Fitbit)

    continuous heart rate activity

    Other: Fitbit · Other: Continuous Glucose Monitor

  • Experimental
    Continuous Glucose Monitor (CGM)

    monitoring daily exercise-related activities

    Other: Fitbit · Other: Continuous Glucose Monitor

Interventions

  • OtherFitbit

    wearable activity tracker

  • OtherContinuous Glucose Monitor

    wearable activity tracker

06

What researchers measure

Primary outcomes

  1. To evaluate the feasibility of the ( PA) Physical Activity intervention.

    The use of CGM through the following criteria: CGM-specific refusal rate \<20% at the participant recruitment phase and protocol adherence rates \>80% at the end of the monitoring period.

    Time frame: through study completion, an average of 1 year

07

Study locations

1 site
  • M D Anderson Cancer Center
    Houston, Texas 77030, United States
08

References and documents

Publications

  • Liao Y, Brannon GE, Rethorst CD, Baum M, Bevers TB, Schembre SM, Basen-Engquist KM. Using Continuous Glucose Monitoring as a Biological Feedback Strategy to Motivate Physical Activity in Cancer Survivors: A Mixed-Methods Pilot Study. Cancer Control. 2025 Jan-Dec;32:10732748251359406. doi: 10.1177/10732748251359406. Epub 2025 Jul 28. PubMed 40719638 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05124405
Lead sponsor
M.D. Anderson Cancer Center
Responsible party
Sponsor
First posted
Nov 18, 2021
Start date
May 24, 2018
Primary completion
Jan 31, 2027 (estimated)
Completion
Jan 31, 2027 (estimated)
Last update
May 20, 2026

Study contacts

Karen Basen-Engquist, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Neoplasms→

Other studies from this sponsor

M.D. Anderson Cancer Center

Start the discussion